Hers vs Hims for GLP-1 Weight Loss: Are They Actually Different?
An independent, side-by-side comparison of Hers and Hims for GLP-1 weight loss programs — pricing, medications, protocols, and patient experience.

Quick Verdict
Best Price
Hims
Starting at $199/mo vs $Infinity/mo
Most Medications
Hers
2 medications vs 2
Best for Beginners
Hims
Async Telehealth, fast onboarding
Head-to-Head Comparison
Pricing Breakdown
Side-by-side pricing for every medication.
| Medication | Hers | Hims | Savings |
|---|---|---|---|
| Semaglutide | Not offered | $199/monthly | Only at Hims |
| Tirzepatide | Not offered | $399/monthly | Only at Hims |
Pros and Cons
Hers
- Clean, women-focused branding and content on hormonal weight management, postpartum weight, and menopause
- Competitive pricing at $199/mo all-in, no hidden membership fees
- Compounded oral semaglutide available
- Fast process
- Backed by a publicly traded company (NYSE: HIMS)
- Free shipping included
- Async-only consultations
- GLP-1 program is identical to Hims
- No compounded tirzepatide option
- No lifestyle coaching, nutrition guidance, or behavioral support (unlike Calibrate, Found, or WeightWatchers Clinic)
- Compounded semaglutide availability subject to ongoing FDA regulatory action
- More expensive than Ro ($149) and Henry Meds ($149) for compounded semaglutide
Hims
- Publicly traded company with financial transparency
- Massive scale — millions of customers across health verticals
- Both compounded and brand-name options
- Free provider consultations included
- No video consultations
- No lab testing included
- GLP-1 only — no other peptides
- Compounded medication availability may vary by state
How They Compare
Our editorial assessment across key dimensions.
In-Depth Comparison
By maria-torres · Last updated March 28, 2026
Hers vs Hims for GLP-1 Weight Loss: Are They Actually Different?
Hers and Hims are both owned by Hims & Hers Health, Inc. (NYSE: HIMS). They share the same provider network, the same pharmacy partners, and the same GLP-1 medication options. So is there any reason to pick one over the other?
The short answer: for GLP-1 weight loss specifically, no. The clinical program is identical. What differs is branding, content, and the broader product ecosystem. This comparison explains exactly what's shared and what's not — so you can decide whether the branding distinction matters to you.
The Core Question: Same Company, Same Program?
Yes. Hers and Hims operate under one corporate entity. The GLP-1 weight loss programs share:
- Same medications (compounded semaglutide, compounded oral semaglutide, brand Wegovy, brand Zepbound)
- Same pricing ($199/mo for compounded semaglutide, $399/mo for brand Zepbound)
- Same provider network (licensed clinicians from a shared pool)
- Same consultation model (async questionnaire, no video)
- Same pharmacy partners (503B compounding facilities for compounded options)
- Same clinical protocols (BMI requirements, prescribing criteria, titration schedules)
If a friend uses Hims for GLP-1 weight loss and you use Hers, you could receive the same medication, at the same dose, prescribed by the same clinician, shipped from the same facility.
How do Hers and Hims compare on price?
There is zero pricing difference between Hers and Hims for any GLP-1 medication or service — both platforms charge the same amounts across every option.
| Medication | Hers | Hims |
|---|---|---|
| Compounded semaglutide (injectable) | $199/mo | $199/mo |
| Compounded oral semaglutide | $199/mo | $199/mo |
| Brand Wegovy | Insurance-dependent | Insurance-dependent |
| Brand Zepbound (tirzepatide) | $399/mo | $399/mo |
| Consultation fee | Included | Included |
| Shipping | Free | Free |
| Membership/subscription fee | None beyond medication cost | None beyond medication cost |
What medications do Hers and Hims offer?
Hers and Hims offer an identical medication selection. Neither platform offers compounded tirzepatide or non-GLP-1 alternatives like metformin, bupropion, or topiramate.
| Medication | Hers | Hims |
|---|---|---|
| Compounded semaglutide (injectable) | ✅ | ✅ |
| Compounded oral semaglutide | ✅ | ✅ |
| Compounded tirzepatide | ❌ | ❌ |
| Brand Wegovy | ✅ | ✅ |
| Brand Zepbound | ✅ ($399/mo) | ✅ ($399/mo) |
| Non-GLP-1 weight loss medications | ❌ | ❌ |
What's Actually Different
1. Branding and Content
This is the primary difference. Hers positions itself as a women's health platform with content addressing:
- Hormonal weight gain — how estrogen, progesterone, and thyroid hormones affect weight
- Postpartum weight management — returning to a healthy weight after pregnancy
- Perimenopause and menopause — metabolic changes during hormonal transitions
- PCOS-related weight — polycystic ovary syndrome and weight management
Hims focuses on:
- Metabolic health framed around fitness and performance
- Clinical weight loss with less hormonal context
- Men's health as the broader platform identity
None of this affects the GLP-1 program itself, but it may affect how comfortable you feel navigating the platform and how relevant the educational content feels.
2. App and Website Experience
The Hers app and website are designed with a women-focused aesthetic — different color palette, imagery, and copy than Hims. The health dashboard, medication tracking, and provider messaging interfaces are functionally the same but visually distinct.
3. Broader Product Catalog
| Category | Hers | Hims |
|---|---|---|
| Weight loss | ✅ | ✅ |
| Birth control | ✅ | ❌ |
| Skincare | ✅ (women's formulations) | ✅ (men's formulations) |
| Hair thinning | ✅ (women's hair loss) | ✅ (men's hair loss) |
| Mental health | ✅ | ✅ |
| Sexual health | ✅ (women's) | ✅ (ED, premature ejaculation) |
If you're likely to use other health services beyond weight loss, the broader catalog determines which platform gives you more value. A woman using birth control and skincare alongside GLP-1s would consolidate under Hers. A man using ED treatment alongside GLP-1s would consolidate under Hims.
Clinical Depth Comparison
| Factor | Hers | Hims |
|---|---|---|
| Consultation type | Async questionnaire | Async questionnaire |
| Provider credentials | Licensed physicians, NPs, PAs | Licensed physicians, NPs, PAs |
| Video consultations | ❌ | ❌ |
| Dietitian access | ❌ | ❌ |
| Lifestyle coaching | ❌ | ❌ |
| Lab testing | ❌ | ❌ |
| Insurance navigation | ❌ | ❌ |
Neither platform offers clinical depth beyond the prescription pathway. No video consultations, no dietitians, no structured coaching. This is the same limitation on both sides.
How They Compare to Other Providers
If you're evaluating Hers or Hims against the broader market, here's how the combined platform stacks up:
| Factor | Hers/Hims | Ro | Mochi Health | Amazon One Medical |
|---|---|---|---|---|
| Compounded semaglutide | $199/mo | $149/mo | $178/mo (incl. membership) | ❌ |
| Brand-name GLP-1s | ✅ | ✅ | ✅ | ✅ |
| Oral semaglutide option | ✅ (compounded) | ❌ | ❌ | ✅ (brand Oral Wegovy) |
| Video consultations | ❌ | ❌ | ✅ | ✅ |
| Dietitian included | ❌ | ❌ | ✅ | ❌ |
| Lifestyle coaching | ❌ | ❌ | ❌ | ❌ |
| In-person option | ❌ | ❌ | ❌ | ✅ |
Hers/Hims price compounded semaglutide at $199/mo — $50/mo more than Ro and Henry Meds. The main differentiator is the compounded oral semaglutide option, which few competitors offer.
Which should you choose: Hers or Hims?
For GLP-1 weight loss specifically, the choice between Hers vs Hims which is better comes down to branding and what other services you plan to use — the clinical program is identical.
Choose Hers if:
- You're a woman who prefers a women's health–focused platform
- You use or plan to use Hers for other services (birth control, skincare, mental health)
- Content about hormonal weight management resonates more than generic clinical content
Choose Hims if:
- You're a man (obviously)
- You use or plan to use Hims for other services (hair loss, ED, skincare)
- Gender-specific branding doesn't matter to you and you just want the most straightforward path
Choose Neither if:
- You want video consultations with a provider → consider Mochi Health
- You want the cheapest compounded semaglutide → consider Ro ($149/mo) or Henry Meds ($149/mo)
- You want compounded tirzepatide → consider Mochi Health ($278/mo) or Henry Meds
- You want integrated lifestyle coaching → consider Found or Calibrate
- You want a primary care relationship → consider Amazon One Medical
What is the bottom line on Hers vs Hims?
Hers and Hims are the same GLP-1 program with different branding. If the women's health positioning and content matter to you, Hers is a perfectly good choice. But don't let branding distract from the more important comparison: Hers/Hims vs. the rest of the market.
At $199/mo for compounded semaglutide, the combined Hers/Hims platform is competitive but not the cheapest way to get semaglutide online. The compounded oral semaglutide option is a genuine differentiator for needle-averse patients. The clinical depth is minimal on both platforms.
Your decision should be less about Hers vs. Hims and more about whether the Hims & Hers model — efficient, async, affordable — is the right fit compared to providers offering clinical depth, in-person care, or lower pricing. When patients ask "is Hers or Hims worth it," the honest answer is: only if you don't need video visits or a dietitian, and only if the $199/mo price point works for your budget.
Frequently Asked Questions
Are Hers and Hims the same company? Yes. Both are brands of Hims & Hers Health, Inc. (NYSE: HIMS). They share a provider network, pharmacy partners, clinical protocols, and pricing for GLP-1 weight loss programs.
Is the Hers or Hims GLP-1 program better for weight loss? Neither. The programs are clinically identical — same medications, same dosing, same provider network. The choice is purely about which branding and product ecosystem fits your life better.
Can a man use Hers for weight loss? Technically yes, but Hers is designed as a women's health platform. Men seeking GLP-1 weight loss would find Hims more relevant, and the clinical program is identical either way.
Is $199/mo a good price for compounded semaglutide? It's competitive but not the cheapest. Ro and Henry Meds both offer compounded semaglutide at $149/mo — $50/mo less. If price is your main concern, those platforms are worth comparing.
Do Hers or Hims offer compounded tirzepatide? No. Neither platform offers compounded tirzepatide. For compounded tirzepatide at $278/mo, Mochi Health is an option.
What makes Hers different from Hims for GLP-1 specifically? Nothing clinically. The only differences are the platform aesthetic, content focus (women's health vs. men's health), and the broader product catalog available alongside weight loss.
Is Hers or Hims worth it if I have insurance that covers Wegovy? Both platforms can facilitate branded Wegovy prescriptions through insurance, but neither offers insurance navigation or prior authorization support. If insurance is your path to GLP-1, Mochi Health or Sequence are better equipped to help.
Related Resources
- Hers Provider Profile — Full Hers breakdown
- Hims Provider Profile — Full Hims breakdown
- Hims vs Ro — How Hims compares to Ro
- Henry Meds vs Hims — Price and service compared
- Best GLP-1 Weight Loss Programs 2026 — All providers ranked
- Semaglutide Dosing Guide — Every formulation, every dose step
Pricing and availability current as of April 2026. Hers and Hims are brands of Hims & Hers Health, Inc. (NYSE: HIMS). Telehealth Ally is not affiliated with Hims & Hers Health.
Related Guides
Best Telehealth Providers for Tirzepatide 2026: Ranked by Price and Care
The best telehealth providers for tirzepatide in 2026, ranked by price, protocol, and care quality. From $278/month compounded to brand Zepbound via insurance. No provider paid for placement.
Read guide →Is Compounded Semaglutide Legal and Safe in 2026?
Is compounded semaglutide still legal? We break down the current FDA rules, 30 new warning letters, SAFE Drugs Act, Hims exiting compounded, and what this means for your prescription.
Read guide →Compounded Tirzepatide 2026: What's Happening and What Patients Should Do
Compounded tirzepatide is under active FDA enforcement as of April 2026 — supply is declining but not yet at zero. The 503B enforcement discretion ended over a year ago (March 2025); the FDA has now issued 50+ warning letters including a 30-letter batch in April 2026. Here's what patients need to know and what to do.
Read guide →